Neurobehavioral Mechanisms of Cocaine Choice

Overview

The objective of this protocol is to use a drug-vs-money choice task, reinforcement learning modeling and fMRI to determine the neurobehavioral and neurobiological decision-making "profile" associated with the decision to take cocaine and the reduced cocaine choice that occurs during behavioral and pharmacological interventions.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Basic Science
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: April 30, 2024

Interventions

  • Drug: Sustained Release d-amphetamine
    • Twice daily administration of active or placebo d-amphetamine
  • Behavioral: Money
    • Three money values offered as alternatives to cocaine

Arms, Groups and Cohorts

  • Experimental: Active Treatment
    • Cocaine choice during d-amphetamine maintenance
  • Placebo Comparator: Placebo Treatment
    • Cocaine choice during placebo maintenance

Clinical Trial Outcome Measures

Primary Measures

  • The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative
    • Time Frame: Choices occur across a 40 minute session
    • The reinforcing effects of cocaine are determined using a reinforcement learning choice task. Subjects complete trials in which they could possibly receive the available cocaine dose or money. Reinforcing effects are measured for a fixed cocaine dose during both d-amphetamine and placebo maintenance and when three amounts of money are available as alternatives to cocaine.

Participating in This Clinical Trial

Inclusion Criteria

  • Recent cocaine use, otherwise healthy Exclusion Criteria:

  • Laboratory results outside of clinically acceptable ranges, history of or current serious physical or psychiatric disease

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Joshua A. Lile, Ph.D.
  • Collaborator
    • National Institute on Drug Abuse (NIDA)
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Joshua A. Lile, Ph.D., Professor of Behavioral Science – University of Kentucky
  • Overall Official(s)
    • Joshua Lile, PhD, Principal Investigator, University of Kentucky

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.